Financial Performance - The net profit attributable to shareholders for the first half of 2024 is approximately CNY 2.94 billion, with a proposed cash dividend of CNY 0.80 per 10 shares, totaling CNY 296.28 million, which accounts for 10.07% of the net profit[4]. - The company's operating revenue for the first half of the year reached ¥139.41 billion, an increase of 5.14% compared to ¥132.59 billion in the same period last year[23]. - Net profit attributable to shareholders was ¥2.94 billion, reflecting a growth of 12.72% from ¥2.61 billion year-on-year[23]. - The basic earnings per share increased to ¥0.79, up 11.27% from ¥0.71 in the previous year[25]. - The total assets of the company at the end of the reporting period were ¥221.34 billion, representing a 4.42% increase from ¥211.97 billion at the end of the previous year[23]. - The total amount of non-recurring gains and losses was ¥236.75 million, after accounting for tax effects and minority interests[26]. - The company reported a significant increase in long-term receivables, which rose by 161.71% to RMB 596.54 million from RMB 227.94 million year-on-year[61]. - The company’s total assets included RMB 62.10 billion in overseas assets, accounting for 2.81% of total assets[62]. Dividend and Share Capital - The total share capital as of June 30, 2024, is 3,703,523,491 shares, which will be used as the basis for the dividend distribution[4]. - The report does not include any capital reserve fund conversion into share capital for this reporting period[4]. - The company will not conduct a capital reserve transfer to increase share capital during this reporting period[129]. - A cash dividend of 0.80 yuan per 10 shares (including tax) is proposed for shareholders, based on a total share capital of 3,703,523,491 shares as of June 30, 2024[129]. Risk Management - There are no significant risks that materially affect the company's operations during the reporting period[5]. - The company emphasizes the importance of risk awareness regarding future plans and development strategies[4]. - The company has implemented strict internal control measures to prevent losses from derivative trading, including clear approval processes and risk management protocols[76]. - The report highlights various risks associated with derivative investments, including market risk, credit risk, and operational risk[76]. Corporate Governance - The report confirms that all board members attended the board meeting, ensuring the accuracy and completeness of the financial report[6]. - The company strictly adheres to the corporate governance code as per the Hong Kong listing rules, although it currently does not meet the gender diversity requirement on the board[134]. - The audit committee has reviewed and approved the accounting treatment methods adopted in the 2024 half-year report[138]. - The company is actively seeking suitable candidates to comply with the gender diversity regulations in the board of directors[134]. Research and Development - The company invested RMB 1.404 billion in R&D, a year-on-year increase of 15.26%, accounting for 11.03% of industrial sales[46]. - The company has 64 new drug pipelines, including 50 innovative drugs, with several in critical research and clinical phases[46]. - The company is actively advancing its cell therapy industrial layout and has initiated clinical trials for its first CAR-T product, B019[45]. - The company is actively responding to the "Healthy China 2030" strategy by increasing innovation investments and optimizing its product offerings[29]. Market and Sales Performance - The pharmaceutical industry segment reported revenue of RMB 12.73 billion, a year-on-year decline of 13.37%, while the pharmaceutical commerce segment generated revenue of RMB 126.68 billion, a year-on-year increase of 7.45%[43]. - The sales amount of the CSO contract promotion business surged to approximately CNY 4 billion, representing a year-on-year increase of 172%[51]. - The sales of non-pharmaceutical businesses, including medical devices and health products, reached approximately CNY 21.8 billion, with a year-on-year growth of about 11.12%[51]. - The sales of health food products from Shanghai Shenyin Microecology Technology Co., Ltd. reached CNY 173 million, reflecting a year-on-year increase of 331%[55]. Investment and Financial Activities - Investment income surged by 223.81% to RMB 246.36 million, compared to a loss of RMB 198.99 million in the previous year[57]. - The company reported a total guarantee amount of 2,524,289,236.08 RMB, which accounts for 3.61% of the company's net assets[167]. - The company has a total of 870,850.00 RMB in credit business with a related party, with actual transactions amounting to 209,257.89 RMB[165]. - The company’s total loan amount from a related party was 209,257.89 RMB during the reporting period[165]. Employee and Stock Options - Shanghai Pharmaceuticals employed 49,234 staff as of June 30, 2024, including 1,674 R&D personnel, focusing on enhancing employee performance and compensation linked to company performance[93]. - The company has implemented an employee stock option incentive plan, with various phases of stock options being exercised as per the announcements[130][132]. - The stock options granted to middle management and core personnel accounted for 77.911% of the total options granted[101]. - The total number of stock options granted under the incentive plan is 24.35572 million, accounting for no more than 1% of the total shares issued by the company as of the report date[3]. Environmental Responsibility - In 2024, the company signed environmental protection responsibility agreements with 20 subsidiaries, enhancing accountability for environmental management[140]. - The group issued a notice outlining six key energy management requirements, aiming to eliminate high-energy-consuming products and improve energy efficiency[141]. - A total of 65 energy-saving technical improvement projects are planned for 2024, with 35 projects completed by the end of the reporting period, expected to save RMB 7.09 million[141].

证券代码：601607 证券简称：上海医药 公告编号：临 2024-085 上海医药集团股份有限公司 2024 年半年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例 A 股每股现金红利 0.08 元 相关日期 H 股 股 东 的 现 金 分 红 有 关 情 况 详 见 本 公 司 在 香 港 联 合 交 易 所 有 限 公 司 网 站 （http://www.hkexnews.hk）发布的落款日期为 2024 年 9 月 2 日的相关公告。 3. 分配方案： 本次利润分配以方案实施前的公司总股本3,704,188,795股（其中A股股本为2,785,116,091 股）为基数，每股派发现金红利 0.08 元（含税），共计派发现金红利 296,335,103.60 元，其中 1. 发放年度：2024 年半年度 2. 分派对象： A 股现金股利人民币 222,809,287.28 元。 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | -- ...

证券代码：601607 证券简称：上海医药 编号：临2024-084 上海医药集团股份有限公司 关于控股股东增持公司 H 股股份的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 2024 年 9 月 13 日，上海医药集团股份有限公司（以下简称"上海医药"或 "公司"）收到上海实业（集团）有限公司（以下简称"上实集团"）通知，上 实集团通过下属全资子公司上实国际投资有限公司（以下简称"上实国际"）增 持了公司 H 股 100,100 股，约占公司总股本（截至 2024 年 9 月 12 日，公司总股 本为 3,704,188,795 股）0.003%。 本次增持前，上实集团持有公司股票 1,352,255,837 股（其中：A 股 1,125,817,837 股，H 股 226,438,000 股），约占公司总股本的 36.506%；本次增 持后，上实集团持有公司股票 1,352,355,937 股（其中：A 股 1,125,817,837 股， H 股 226,538,100 股），约占公司总股本的 36.509 ...

证券代码：601607 证券简称：上海医药 编号：临2024-083 上海医药集团股份有限公司 关于控股股东 H 股增持计划实施完毕的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 上海医药集团股份有限公司（以下简称"本公司"）于 2023 年 9 月 11 日收 到上海实业（集团）有限公司（以下简称"上实集团"）通知，上实集团计划在 此后的 12 个月内通过下属全资子公司上实国际投资有限公司（以下简称"上实 国际"）于二级市场增持本公司 H 股股份，增持比例不超过本公司已发行总股本 的 2%（详见公司公告临 2023-076 号）。 截至 2024 年 9 月 10 日香港联合交易所有限公司收市，上实集团增持本公司 H 股股份计划已经实施完毕。本次增持期间内，上实集团通过上实国际增持了本 公司 H 股股份共计 7,899,600 股，约占本公司已发行 H 股股份总数（即 919,072,704 股）的 0.860%，占已发行股份总数（即 3,704,188,795 股，公司截 至 2024 年 9 月 10 日的 ...

证券代码：601607 证券简称：上海医药 编号：2024-004 上海医药集团股份有限公司 投资者关系活动记录表 | --- | --- | --- | |-------------|---------------------------|------------------------------------------------------------| | | | | | 投 资 者 关 | □ | 特定对象调研 □分析师会议 | | 系 活 动 类 | □ | 媒体采访 业绩说明会 | | 别 | □ | 新闻发布会 □路演活动 | | | □ | 现场参观 □其他 | | 参 与 单 位 | | 线下参与机构：中信证券、银河证券、中金公司、华安证券、湘财 | | 名称 | | 证券、高毅资产、远信投资、汇添富基金、国信证券、永盈基金、 | | | | 国君资管、海通资管、华泰证券、天风证券、山西证券、瑞银证 | | | | 券、招商证券、摩根士丹利证券、嘉实基金、浙商证券、摩根基 | | | 金、海通国际等 | 87 人次，同时还有 776 人次通过直播平台及上证 | | | 路演中心于线上听会 ...

Investment Rating - The report maintains an "Outperform" rating for Shanghai Pharma (2607 HK) with a target price of HKD 13.82, down 5.0% from previous estimates [3][5][17]. Core Insights - Shanghai Pharma's 1H24 results showed revenue of CNY 139.4 billion, a year-on-year increase of 5.1%, with a notable growth in the Contract Sales Organization (CSO) business, which achieved sales of CNY 4.0 billion, up 172% year-on-year [11][12]. - The pharmaceutical manufacturing segment faced challenges, reporting a revenue decline of 13.4% year-on-year, primarily due to price reductions in products from SPH No.1 Biochemical & Pharmaceutical [12][14]. - The company successfully introduced 8 import varieties and added 15 new SPD projects in 1H24, contributing to its growth despite the overall industry pressure [11][12]. Revenue and Profitability - In 1H24, Shanghai Pharma's gross profit margin (GPM) was 11.6%, down 1.3 percentage points year-on-year, while the net profit attributable to shareholders was CNY 2.94 billion, reflecting a 12.7% increase year-on-year [14][13]. - The report projects revenue for 2024, 2025, and 2026 to be CNY 277.8 billion, CNY 299.9 billion, and CNY 323.5 billion respectively, with growth rates of 6.7%, 8.0%, and 7.9% [16][17]. Accounts Receivable - As of 1H24, Shanghai Pharma's accounts receivable totaled CNY 80.9 billion, with a significant portion due within one year, indicating potential cash flow management challenges [15][4]. Valuation Methodology - The valuation is based on a discounted cash flow (DCF) model using a WACC of 6.2% and a perpetual growth rate of 3%, leading to the target price of HKD 13.82 [5][17].

Investment Rating - The report assigns a "Recommended" rating to Shanghai Pharmaceuticals [3] Core Views - The company reported a revenue of 139.41 billion yuan for the first half of 2024, representing a 5.14% increase year-on-year, with pharmaceutical commercial revenue growing by 7.45% to 126.68 billion yuan, while pharmaceutical industrial revenue decreased by 13.4% to 12.73 billion yuan. The net profit attributable to shareholders was 2.94 billion yuan, up 12.72% [1] - In Q2 2024, the company achieved a revenue of 69.26 billion yuan, a 4.36% increase, and a net profit of 1.40 billion yuan, reflecting a significant growth of 28.15%. The growth in profit outpaced revenue growth due to non-recurring asset impairment factors from the previous year [1] - The company is focusing on innovation and R&D, with an investment of 1.40 billion yuan in R&D for H1 2024, a 15.26% increase, accounting for 11.03% of industrial sales. The company has multiple new drug applications in progress, including a self-developed product for hypertension [1] Summary by Sections Financial Performance - For H1 2024, Shanghai Pharmaceuticals reported total revenue of 139.41 billion yuan, with a net profit of 2.94 billion yuan, and a significant increase in net profit margin [1] - The company’s operating cash flow decreased by 68.56% to 515 million yuan, indicating potential liquidity concerns [1] Business Segments - The pharmaceutical commercial segment showed robust growth, driven by CSO import agency and vaccine promotion, with CSO sales reaching 4 billion yuan, a 172% increase year-on-year [1] - The non-pharmaceutical business, including medical devices and health products, also grew, with new SPD projects generating approximately 21.8 billion yuan in revenue, an 11.12% increase [1] R&D and Innovation - The company is advancing its R&D efforts, with a focus on traditional Chinese medicine, achieving revenue of 5.19 billion yuan in H1 2024 from its Chinese medicine segment [1] - The company is actively developing major traditional Chinese medicine products and brands, enhancing its competitive edge in the market [1] Management and Strategy - The management is implementing cost reduction and efficiency improvement measures through platform integration and refined management practices, aiming for high-quality growth [2] - The company’s strategic focus on collaboration between its commercial and industrial segments is expected to enhance its competitive advantage [2]

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected stock price increase of over 20% relative to the market benchmark index within the next six months [6][17]. Core Views - The company reported a revenue of 139.4 billion yuan for the first half of 2024, representing a year-on-year growth of 5.1%, with a net profit attributable to shareholders of 2.94 billion yuan, up 12.7% [1]. - The commercial segment showed steady growth, with Q2 revenue reaching 63.5 billion yuan, a 6.7% increase, and a notable performance in the CSO business, which saw a revenue surge of 217% [2]. - The industrial segment faced revenue pressure, with Q2 income down 16.1% to 5.79 billion yuan, primarily due to a decline in a subsidiary's performance, yet profitability improved with a net profit of 640 million yuan, up 2.9% [3]. Financial Analysis - The company achieved a gross margin of 11.75% and a net margin of 2.5% in Q2, with operational efficiency indicators showing an increase in accounts receivable turnover days to 99.3 days, while inventory turnover days decreased to 52.5 days [4]. - The forecast for revenue from 2024 to 2026 is projected at 289.8 billion yuan, 320.5 billion yuan, and 351.3 billion yuan respectively, with corresponding net profits of 5.24 billion yuan, 5.84 billion yuan, and 6.54 billion yuan, indicating strong growth potential [5][14].

公司快报 2024 年 08 月 27 日 上海医药(601607.SH) 南北整合阶段性成果突出，创新业务蓬 勃发展 事件：公司发布 2024 年中报，整体业绩稳健，单 Q2 工商业贡 献利润稳增。 2024H1 公司实现营业收入 1,394.13 亿元/+5.14%，其中：医药工 业收入 127.34 亿元/-13.37%，医药商业收入 1,266.79 亿元 /+7.45%；归母净利润 29.42 亿元/+12.72%，其中：工业、商业贡 献利润分别约为 13.12 亿元/-1.20%、17.93 亿元/+1.30%，主要 参股企业贡献利润 3.41 亿元；扣非净利润 27.05 亿元/+23.00%。 单 Q2 来看，公司实现营收 692.60 亿元/+4.36%，其中：工业收入 约 57.90/-16.06%，商业收入约 634.70/+6.73%；归母净利润 14.00 亿元/+28.15%，其中：商业、工业贡献利润分别约为 9.61 亿元 /+5.72%、6.38 亿元/+2.90%，单 Q2 公司工业及商业板块经营性 利润实现稳定增长。 Q2 费用端优化，盈利水平有所提升。2024H1 公司销 ...

Investment Rating - The report maintains a "Buy" rating for the company, with expected EPS of 1.43/1.58/1.74 yuan for 2024-2026 and corresponding PE ratios of 13.09/11.87/10.79x [5] Core Views - The company demonstrates robust revenue and profit growth, with 2024H1 revenue reaching 139.41 billion yuan (+5.14%) and net profit attributable to parent company of 2.94 billion yuan (+12.72%) [3] - The pharmaceutical commercial segment shows strong performance, with CSO contract promotion business achieving sales of approximately 4 billion yuan, a 172% year-on-year increase [3] - The company continues to optimize its expense control, with sales expense ratio decreasing by 1.12 percentage points to 4.71% in 2024H1 [3] Business Performance Pharmaceutical Commercial Segment - Achieved revenue of 126.68 billion yuan (+7.45%) in 2024H1, with distribution business contributing 127.03 billion yuan (+6.91%) [3] - Successfully introduced 8 new imported agency products and expanded SPD cooperation projects, adding 15 new SPD projects in the first half of 2024 [3] Pharmaceutical Industrial Segment - Generated revenue of 12.73 billion yuan (-13.37%) in 2024H1, mainly due to one-time impact of price reductions [3] - Traditional Chinese medicine business maintained stable growth, with industrial revenue reaching 5.19 billion yuan (+1.41%) [3] R&D and Innovation - Increased R&D investment to 1.40 billion yuan (+15.26%) in 2024H1, accounting for 11.03% of industrial sales [4] - Currently has 64 new drug pipelines in clinical application or subsequent research stages, including 50 innovative drugs [4] Financial Projections - Forecasts net profit attributable to parent company of 5.31/5.85/6.44 billion yuan for 2024-2026, with revenue growth rates of 10.37%/10.17%/10.09% [6] - Expects gross margin to improve from 12.0% in 2023 to 13.1% by 2026, with net margin stable at around 1.8% [7] Strategic Development - Accelerated integration of marketing systems and established a new pharmaceutical sales company to enhance terminal self-operation capabilities [4] - Strengthened provincial platform construction and formed a new pattern of commercial integrated development [4]